Terms: = Liver cancer AND KIT, C-Kit, 3815, ENSG00000157404, CD117, SCFR, P10721 AND Clinical Outcome
14 results:
1. Computational Analysis of Cholangiocarcinoma Phosphoproteomes Identifies Patient-Specific Drug Targets.
Khorsandi SE; Dokal AD; Rajeeve V; Britton DJ; Illingworth MS; Heaton N; Cutillas PR
Cancer Res; 2021 Nov; 81(22):5765-5776. PubMed ID: 34551960
[TBL] [Abstract] [Full Text] [Related]
2. MiR-138-5p predicts negative prognosis and exhibits suppressive activities in hepatocellular carcinoma HCC by targeting FOXC1.
Yang G; Guo S; Liu HT; Yang G
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8788-8800. PubMed ID: 32964967
[TBL] [Abstract] [Full Text] [Related]
3. PEX5, a novel target of microRNA-31-5p, increases radioresistance in hepatocellular carcinoma by activating Wnt/β-catenin signaling and homologous recombination.
Wen J; Xiong K; Aili A; Wang H; Zhu Y; Yu Z; Yao X; Jiang P; Xue L; Wang J
Theranostics; 2020; 10(12):5322-5340. PubMed ID: 32373215
[No Abstract] [Full Text] [Related]
4. Laminin 521 enhances self-renewal via STAT3 activation and promotes tumor progression in colorectal cancer.
Qin Y; Shembrey C; Smith J; Paquet-Fifield S; Behrenbruch C; Beyit LM; Thomson BNJ; Heriot AG; Cao Y; Hollande F
Cancer Lett; 2020 Apr; 476():161-169. PubMed ID: 32105676
[TBL] [Abstract] [Full Text] [Related]
5. Low‑intensity ultrasound enhances the antitumor effects of doxorubicin on hepatocellular carcinoma cells through the ROS‑miR‑21‑PTEN axis.
Xia C; Zeng H; Zheng Y
Mol Med Rep; 2020 Mar; 21(3):989-998. PubMed ID: 32016465
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic Implications of Multiplex Detection of
Kim MK; Woo SM; Park B; Yoon KA; Kim YH; Joo J; Lee WJ; Han SS; Park SJ; Kong SY
Clin Chem; 2018 Apr; 64(4):726-734. PubMed ID: 29352043
[TBL] [Abstract] [Full Text] [Related]
7. Evaluation of the COBAS® TaqMan® system in patients with low hepatitis B virus DNA undetectable with PCR assay kit.
Zhou J; Hu WY; Li YC; Luo HX; Li J; Li CH; Tong JJ; Chen CJ; Zhang LL
Eur Rev Med Pharmacol Sci; 2016 Sep; 20(18):3886-3890. PubMed ID: 27735026
[TBL] [Abstract] [Full Text] [Related]
8. Combination antiangiogenic therapy and radiation in head and neck cancers.
Hsu HW; Wall NR; Hsueh CT; Kim S; Ferris RL; Chen CS; Mirshahidi S
Oral Oncol; 2014 Jan; 50(1):19-26. PubMed ID: 24269532
[TBL] [Abstract] [Full Text] [Related]
9. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.
Akiba J; Nakashima O; Hattori S; Tanikawa K; Takenaka M; Nakayama M; Kondo R; Nomura Y; Koura K; Ueda K; Sanada S; Naito Y; Yamaguchi R; Yano H
Am J Surg Pathol; 2013 Apr; 37(4):496-505. PubMed ID: 23388123
[TBL] [Abstract] [Full Text] [Related]
10. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma.
Yamashita T; Honda M; Nakamoto Y; Baba M; Nio K; Hara Y; Zeng SS; Hayashi T; Kondo M; Takatori H; Yamashita T; Mizukoshi E; Ikeda H; Zen Y; Takamura H; Wang XW; Kaneko S
Hepatology; 2013 Apr; 57(4):1484-97. PubMed ID: 23174907
[TBL] [Abstract] [Full Text] [Related]
11. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.
Harmon CS; DePrimo SE; Raymond E; Cheng AL; Boucher E; Douillard JY; Lim HY; Kim JS; Lechuga MJ; Lanzalone S; Lin X; Faivre S
J Transl Med; 2011 Jul; 9():120. PubMed ID: 21787417
[TBL] [Abstract] [Full Text] [Related]
12. Prognosis of gastrointestinal stromal tumors.
Bertin M; Angriman I; Scarpa M; Mencarelli R; Ranzato R; Ruffolo C; Polese L; Iacobone M; D'Amico DF
Hepatogastroenterology; 2007; 54(73):124-8. PubMed ID: 17419245
[TBL] [Abstract] [Full Text] [Related]
13. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
[TBL] [Abstract] [Full Text] [Related]
14. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins.
Plaat BE; Hollema H; Molenaar WM; Torn Broers GH; Pijpe J; Mastik MF; Hoekstra HJ; van den Berg E; Scheper RJ; van der Graaf WT
J Clin Oncol; 2000 Sep; 18(18):3211-20. PubMed ID: 10986053
[TBL] [Abstract] [Full Text] [Related]
